Axsome Therapeutics (AXSM) News Today $137.54 +8.45 (+6.54%) As of 02:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $200.00 at HC WainwrightHC Wainwright lifted their target price on Axsome Therapeutics from $190.00 to $200.00 and gave the company a "buy" rating in a report on Thursday.February 21 at 8:15 AM | marketbeat.comFY2028 Earnings Estimate for AXSM Issued By Leerink PartnrsAxsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Equities research analysts at Leerink Partnrs cut their FY2028 EPS estimates for shares of Axsome Therapeutics in a report released on Tuesday, February 18th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earninFebruary 21 at 7:04 AM | marketbeat.comEquities Analysts Set Expectations for AXSM FY2028 EarningsFebruary 21 at 3:31 AM | americanbankingnews.comRoyal Bank of Canada Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) StockFebruary 21 at 2:43 AM | americanbankingnews.comTruist Financial Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) StockTruist Financial raised their price target on shares of Axsome Therapeutics from $190.00 to $200.00 and gave the company a "buy" rating in a research note on Wednesday.February 20 at 12:21 PM | marketbeat.comCantor Fitzgerald Reaffirms Overweight Rating for Axsome Therapeutics (NASDAQ:AXSM)Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $153.00 price target on shares of Axsome Therapeutics in a research note on Wednesday.February 20 at 10:37 AM | marketbeat.comRoyal Bank of Canada Increases Axsome Therapeutics (NASDAQ:AXSM) Price Target to $192.00Royal Bank of Canada boosted their price objective on Axsome Therapeutics from $143.00 to $192.00 and gave the company an "outperform" rating in a research note on Wednesday.February 20 at 10:37 AM | marketbeat.comAxsome Therapeutics price target raised to $200 from $190 at H.C. WainwrightFebruary 20 at 10:33 AM | markets.businessinsider.comAxsome Therapeutics, Inc. (AXSM): the Best Performing Healthcare Stock So Far in 2025February 20 at 10:33 AM | msn.comAxsome Q4 Earnings: Revenues Rising, Skepticism LingeringFebruary 20 at 8:15 AM | seekingalpha.comNeedham & Company LLC Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) StockNeedham & Company LLC increased their price objective on shares of Axsome Therapeutics from $133.00 to $153.00 and gave the company a "buy" rating in a research note on Wednesday.February 20 at 8:05 AM | marketbeat.comAxsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $153.00 at Needham & Company LLCFebruary 20 at 4:05 AM | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $200.00February 20 at 3:19 AM | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) Earns Outperform Rating from William BlairFebruary 20 at 2:05 AM | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) Shares Gap Down - Time to Sell?Axsome Therapeutics (NASDAQ:AXSM) Shares Gap Down - Here's WhyFebruary 19 at 9:53 PM | marketbeat.comAxsome Therapeutics price target raised to $192 from $143 at RBC CapitalFebruary 19 at 12:20 PM | markets.businessinsider.comAxsome Therapeutics price target raised to $200 from $190 at TruistFebruary 19 at 12:20 PM | markets.businessinsider.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Q4 2024 Earnings Call TranscriptFebruary 19 at 12:20 PM | msn.comWilliam Blair Reiterates Outperform Rating for Axsome Therapeutics (NASDAQ:AXSM)William Blair reaffirmed an "outperform" rating on shares of Axsome Therapeutics in a report on Tuesday.February 19 at 10:14 AM | marketbeat.comAxsome Therapeutics (NASDAQ:AXSM) Announces Earnings Results, Beats Expectations By $0.01 EPSAxsome Therapeutics (NASDAQ:AXSM - Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.96) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%.February 19 at 8:15 AM | marketbeat.comAxsome Therapeutics (NASDAQ:AXSM) Releases Earnings Results, Beats Expectations By $0.01 EPSAxsome Therapeutics (NASDAQ:AXSM - Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.96) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%.February 19 at 7:57 AM | marketbeat.comPeregrine Capital Management LLC Raises Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Peregrine Capital Management LLC lifted its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 21.2% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 87,187 shares of the company's stock after acquiring an additional 15,258February 19 at 5:15 AM | marketbeat.comAxsome Therapeutics (NASDAQ:AXSM) Given "Outperform" Rating at William BlairWilliam Blair reissued an "outperform" rating on shares of Axsome Therapeutics in a research report on Tuesday.February 19 at 2:56 AM | marketbeat.comAxsome Therapeutics, Inc. (AXSM) Q4 2024 Earnings Call TranscriptFebruary 18 at 4:31 PM | seekingalpha.comAxsome's AXS-05 In Alzheimer's Agitation Could Be Billion Dollar Opportunity, Says AnalystFebruary 18 at 4:31 PM | benzinga.comAxsome Therapeutics (AXSM) Q4 2024 Earnings Call TranscriptFebruary 18 at 4:31 PM | msn.comAxsome Therapeutics reports Q4 EPS ($1.54), consensus ($1.00)February 18 at 11:18 AM | markets.businessinsider.comAxsome Therapeutics expects cash to fund operations into cash flow positivityFebruary 18 at 11:18 AM | markets.businessinsider.comAxsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateFebruary 18 at 11:18 AM | finance.yahoo.comAxsome Therapeutics, Inc. 2024 Q4 - Results - Earnings Call PresentationFebruary 18 at 8:29 AM | seekingalpha.comAxsome Therapeutics Revenue Surges 66%February 18 at 8:06 AM | fool.comStrategic Financial Concepts LLC Purchases New Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Strategic Financial Concepts LLC acquired a new position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 30,713 shares of the company's stock, valued at appFebruary 18 at 4:22 AM | marketbeat.comThis Stock Is Already Up by 55% in 2025: Is It Too Late to Buy?February 16, 2025 | fool.comAxsome Therapeutics (AXSM) to Release Quarterly Earnings on TuesdayAxsome Therapeutics (NASDAQ:AXSM) will be releasing earnings before the market opens on Tuesday, February 18, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=292360)February 16, 2025 | marketbeat.comInsider Selling: Axsome Therapeutics, Inc. (NASDAQ:AXSM) CFO Sells 3,000 Shares of StockAxsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) CFO Nick Pizzie sold 3,000 shares of the business's stock in a transaction on Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the transaction, the chief financial officer now directly owns 42,187 shares of the company's stock, valued at approximately $5,529,450.09. The trade was a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.February 16, 2025 | marketbeat.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) CFO Sells $393,210.00 in StockFebruary 15, 2025 | insidertrades.comAxsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $160.00February 15, 2025 | americanbankingnews.comFY2025 Earnings Estimate for AXSM Issued By Leerink PartnrsFebruary 15, 2025 | americanbankingnews.comEquities Analysts Offer Predictions for AXSM FY2025 EarningsFebruary 15, 2025 | americanbankingnews.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Receives $134.00 Consensus Target Price from AnalystsFebruary 14, 2025 | americanbankingnews.comQ1 Earnings Forecast for AXSM Issued By Leerink PartnrsFebruary 14, 2025 | americanbankingnews.comCantor Fitzgerald Estimates AXSM FY2025 EarningsAxsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Axsome Therapeutics in a research note issued to investors on Tuesday, February 11th. Cantor Fitzgerald analyst C. Duncan expects that tFebruary 13, 2025 | marketbeat.comLeerink Partnrs Brokers Decrease Earnings Estimates for AXSMAxsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Analysts at Leerink Partnrs reduced their FY2025 earnings per share estimates for shares of Axsome Therapeutics in a report released on Monday, February 10th. Leerink Partnrs analyst M. Goodman now anticipates that the company will earn ($4.February 13, 2025 | marketbeat.comWells Fargo & Company Boosts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $160.00Wells Fargo & Company lifted their price target on shares of Axsome Therapeutics from $140.00 to $160.00 and gave the company an "overweight" rating in a research report on Wednesday.February 13, 2025 | marketbeat.comAxsome Therapeutics' (AXSM) "Buy" Rating Reiterated at HC WainwrightFebruary 13, 2025 | americanbankingnews.comDeutsche Bank Aktiengesellschaft Begins Coverage on Axsome Therapeutics (NASDAQ:AXSM)February 13, 2025 | americanbankingnews.comBank of America Raises Axsome Therapeutics (NASDAQ:AXSM) Price Target to $167.00February 13, 2025 | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $195.00February 13, 2025 | americanbankingnews.comAxsome Therapeutics price target raised to $160 from $140 at Wells FargoFebruary 12, 2025 | markets.businessinsider.comAxsome Therapeutics (NASDAQ:AXSM) Stock Price Expected to Rise, Wells Fargo & Company Analyst SaysWells Fargo & Company boosted their price target on shares of Axsome Therapeutics from $140.00 to $160.00 and gave the stock an "overweight" rating in a research report on Wednesday.February 12, 2025 | marketbeat.com Get Axsome Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Email Address AXSM Media Mentions By Week AXSM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AXSM News Sentiment▼0.460.60▲Average Medical News Sentiment AXSM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AXSM Articles This Week▼559▲AXSM Articles Average Week Get Axsome Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TEVA News SMMT News GMAB News ITCI News VTRS News MRNA News RDY News PCVX News SRPT News QGEN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AXSM) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Axsome Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
